Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Autolus Therapeutics plc (Nasdaq: AUTL) will release its second quarter 2022 financial results and operational highlights before the U.S. market opens on August 4, 2022. A conference call and webcast will be held at 8:30 am ET/1:30 pm BST to discuss these results and provide a business update. Participants must pre-register to receive dial-in information. The webcast will also be available for replay in the events section of Autolus' website.
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its Q2 2022 financial results and operational highlights on August 4, 2022, prior to the U.S. market opening. A conference call and webcast featuring management will occur at 8:30 am ET to discuss the results and provide an update on the company's business. Participants can pre-register for the call to receive dial-in numbers and PINs. The audio webcast will also be accessible on the company's website.
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in William Blair’s Biotech Focus Conference 2022 in New York City on July 12. CEO Dr. Christian Itin will join a panel discussion titled ‘Operationalizing Cell Therapies’ from 8:55 to 10:15 am ET. The company aims to advance next-generation programmed T cell therapies for cancer treatment. With proprietary technologies, Autolus develops targeted T cell therapies designed to combat various cancers, focusing on hematological malignancies and solid tumors.
Autolus Therapeutics (Nasdaq: AUTL) announced significant clinical data at the European Hematology Association Congress from June 9-12, 2022. Key highlights include:
- AUTO4: Shows promising activity for T cell lymphoma with favorable safety profiles.
- AUTO1/22: Demonstrates strong remission rates in children with B-ALL, even those unresponsive to existing CAR T therapies.
- Obe-cel: Exhibits sustained efficacy in B-NHL and emerging activity in Primary CNS Lymphoma.
A conference call will take place on June 13, 2022, at 7:30 AM EST to discuss these findings.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced its Annual General Meeting (AGM) to be held on June 28, 2022, in London. The official notice for shareholders details the meeting's agenda, which includes ordinary and special resolutions. The company will announce the results of the voting via a press release following the AGM. Autolus is focused on developing advanced T cell therapies for cancer treatment, utilizing proprietary technologies to create targeted therapies aimed at hematological malignancies and solid tumors.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in the Jefferies Healthcare Conference in New York City on June 9, 2022. CEO Dr. Christian Itin will engage in a Fireside Chat from 9:00 to 9:30 am ET. The company will also hold one-on-one investor meetings at the event. An audio webcast of the Fireside Chat will be available on Autolus' website, with an archived version accessible for a limited period post-conference. Autolus specializes in programmed T cell therapies aimed at treating various cancers.
Autolus Therapeutics (AUTL) has announced the online publication of four abstracts for the European Hematology Association (EHA) Congress, scheduled for June 9-12, 2022. Notable presentations include early clinical data for AUTO4 targeting peripheral T cell lymphoma and AUTO1/22 for pediatric B-cell acute lymphoblastic leukemia. CEO Christian Itin expressed optimism about the early safety and efficacy data, particularly for the lead asset, obe-cel. A conference call on June 13, 2022, will detail these findings and propose next steps for the pipeline.
Autolus Therapeutics (NASDAQ: AUTL) reported operational and financial results for Q1 2022, revealing a net loss of $37.1 million, or $(0.41) per share. Cash reserves decreased to $268.6 million from $310.3 million as of December 31, 2021. Significant updates include the successful futility analysis of the FELIX clinical trial for obe-cel in adult B-cell Acute Lymphoblastic Leukemia, which received RMAT designation from the FDA. Initial data from the trial is expected in late 2022. Autolus also continues its pipeline developments, with upcoming presentations at the EHA Congress in June.
Autolus Therapeutics plc (Nasdaq: AUTL) announced the presentation of three innovative cell programming approaches at the American Society of Gene & Cell Therapy (ASGCT) from May 16-19, 2022. Dr. Martin Pule emphasized the importance of enhancing T cell therapy through improved targeting and activity for better patient outcomes. The posters include:
- Enhancing CAR T Cell Therapy Using Cytokine Receptors
- Fas-CD40 Chimera for Better T Cell Effectiveness in Solid Tumors
- Minocycline as a Tuning Control for CAR T Cell Activation
These advancements aim to enhance cancer treatment outcomes.
Autolus Therapeutics plc (Nasdaq: AUTL) has received RMAT designation from the FDA for its lead gene therapy, obe-cel, designed for adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL). This designation recognizes the therapy's potential to fulfill unmet medical needs and facilitates the drug development process. obe-cel has also received PRIME and ILAP designations in Europe. The ongoing FELIX Phase 2 trial aims to enroll 140 patients across multiple centers. This milestone underscores the importance of obe-cel in addressing critical treatment gaps in adult B-ALL.